Likewise, a current breast cancer study is combining genomics, imaging, and AI to uncover the relationships between disease features, establish predictive models for the sensitivity of HER2 positive breast cancer to targeted therapy, and elucidate the imaging genomic characteristics of the therapeutic targets of each breast cancer subtype (NCT04461990). This evidence concerns the gene ERBB2 and breast cancer.